Search for: "Mayo v. State" Results 101 - 120 of 833
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Dec 2019, 7:00 am by IPWatchdog
The United States Office of the Solicitor General has filed its brief in response to the Supreme Court’s March request for views in Hikma Pharmaceuticals v. [read post]
20 Jul 2022, 8:27 am by Holman
Cir. 2019), the Federal Circuit’s current interpretation of the Supreme Court’s decision in Mayo v. [read post]
21 Mar 2012, 6:21 am by Dennis Crouch
Hovenkamp, Creation without Restraint: Promoting Liberty and Rivalry in Innovation 112 (2012) ("One problem with [process] patents is that the more abstractly their claims are stated, the more difficult it is to determine precisely what they cover. [read post]
28 Jan 2011, 2:29 pm by Arnstein.com
McKenzie will present the audio webcast (or teleseminar)  “Regulatory Deference in Light of Mayo Foundation v. [read post]
29 Mar 2012, 6:05 am by Lawrence B. Ebert
" For example, recall Brown, which overturned the Plessy v. [read post]
29 Jun 2010, 3:01 pm by Dennis Crouch
Kappos and the Anti-State-Street-Majority Mayo v. [read post]
19 Dec 2013, 7:09 pm by Mary Pat Dwyer
The petition of the day is: Mayo v. [read post]
23 Jul 2012, 12:00 am by Antoinette Konski
Surprisingly, the panel took the discussion to claim 20 which was stated to be the closest in relevance to Mayo. [read post]
9 Jan 2020, 11:08 am by Courtenay C. Brinckerhoff
Responding to the invitation from the Supreme Court, the Solicitor General for the United States has filed an amicus brief for the United States in Hikma Pharmaceuticals USC Inc. v. [read post]
30 Nov 2011, 10:13 am by Steve
Next week the United States Supreme Court will hear argument in a patent case styled Mayo Collaborative Services v. [read post]
20 Mar 2012, 9:22 pm by Patent Docs
By Kwame Mensah -- In an opinion published earlier today, the Supreme Court unanimously held that claims directed to the relationship between the concentrations of blood metabolites and response to a therapeutic drug in two patents owned by Prometheus Laboratories, Inc. were unpatentable, stating that they "effectively claim the underlying laws of nature themselves. [read post]